Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2007 1
2008 3
2009 7
2010 6
2011 4
2012 6
2013 9
2014 15
2015 16
2016 13
2017 14
2018 20
2019 35
2020 26
2021 25
2022 25
2023 23
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for yunchao huang
Search for Yunhao Huang instead (2 results)
CAR-T cell therapy for lung cancer: Potential and perspective.
Chen L, Chen F, Li J, Pu Y, Yang C, Wang Y, Lei Y, Huang Y. Chen L, et al. Among authors: huang y. Thorac Cancer. 2022 Apr;13(7):889-899. doi: 10.1111/1759-7714.14375. Epub 2022 Mar 15. Thorac Cancer. 2022. PMID: 35289077 Free PMC article. Review.
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Yang Z, Shi W, Zou J, Zhou C; CameL-sq Study Group. Ren S, et al. Among authors: huang y. J Thorac Oncol. 2022 Apr;17(4):544-557. doi: 10.1016/j.jtho.2021.11.018. Epub 2021 Dec 16. J Thorac Oncol. 2022. PMID: 34923163 Free article. Clinical Trial.
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study.
Li N, Tan F, Chen W, Dai M, Wang F, Shen S, Tang W, Li J, Yu Y, Cao W, Xu Y, Qin C, Zhao L, Zhu M, Guo L, Wu Z, Yang Z, Zheng Y, Chen H, Liu Y, Wei D, Dong D, Cao J, Zhang S, Yan S, Wang N, Du L, Shen H, Wu N, He J; National Lung Cancer Screening programme group. Li N, et al. Lancet Respir Med. 2022 Apr;10(4):378-391. doi: 10.1016/S2213-2600(21)00560-9. Epub 2022 Mar 8. Lancet Respir Med. 2022. PMID: 35276087
YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression.
Shi Y, Fan S, Wu M, Zuo Z, Li X, Jiang L, Shen Q, Xu P, Zeng L, Zhou Y, Huang Y, Yang Z, Zhou J, Gao J, Zhou H, Xu S, Ji H, Shi P, Wu DD, Yang C, Chen Y. Shi Y, et al. Among authors: huang y. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6. Nat Commun. 2019. PMID: 31653849 Free PMC article.
The existence of a nonclassical TCA cycle in the nucleus that wires the metabolic-epigenetic circuitry.
Liu X, Si W, He L, Yang J, Peng Y, Ren J, Liu X, Jin T, Yu H, Zhang Z, Cheng X, Zhang W, Xia L, Huang Y, Wang Y, Liu S, Shan L, Zhang Y, Yang X, Li H, Liang J, Sun L, Shang Y. Liu X, et al. Among authors: huang y. Signal Transduct Target Ther. 2021 Nov 3;6(1):375. doi: 10.1038/s41392-021-00774-2. Signal Transduct Target Ther. 2021. PMID: 34728602 Free PMC article.
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li D, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S. Lu S, et al. Among authors: huang y. JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735. JAMA. 2024. PMID: 38227033 Clinical Trial.
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J; CameL Study Group. Zhou C, et al. Among authors: huang y. Lancet Respir Med. 2021 Mar;9(3):305-314. doi: 10.1016/S2213-2600(20)30365-9. Epub 2020 Dec 18. Lancet Respir Med. 2021. PMID: 33347829 Clinical Trial.
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, Gu K, Tao M, Wang X, Cui C, Xu N, Xiao J, Gao Q, Liu Y, Zhang T, Bai Y, Li W, Zhang Y, Dai G, Ma D, Zhang J, Bai C, Huang Y, Liao W, Wu L, Chen X, Yang Y, Wang J, Ji S, Zhou H, Wang Y, Ma Z, Wang Y, Peng B, Sun J, Mancao C. Xu J, et al. Among authors: huang y. Nat Commun. 2022 Feb 14;13(1):857. doi: 10.1038/s41467-022-28408-3. Nat Commun. 2022. PMID: 35165274 Free PMC article. Clinical Trial.
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Tai Y, Ma X, Shi W; CameL Study Group. Zhou C, et al. Among authors: huang y. J Thorac Oncol. 2023 May;18(5):628-639. doi: 10.1016/j.jtho.2022.12.017. Epub 2023 Jan 13. J Thorac Oncol. 2023. PMID: 36646210 Clinical Trial.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Yang JC, et al. Among authors: huang y. Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12. Lancet Oncol. 2015. PMID: 25589191 Free article. Clinical Trial.
245 results